HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.

AbstractOBJECTIVES:
Pharmacokinetic studies in animal models are important for assessing the prophylactic potential of antiretroviral drugs for HIV prevention. This study sought to identify clinically relevant doses of the marketed integrase inhibitors raltegravir, elvitegravir and dolutegravir in macaques and investigate drug penetration and antiviral activity in mucosal secretions.
METHODS:
Macaques received one oral dose of raltegravir, elvitegravir or dolutegravir alone or in combination with emtricitabine and tenofovir disoproxil fumarate followed by drug level measurements in blood and rectal and vaginal secretions. Antiviral activity was investigated in TZM-bl cells exposed to SHIV162p3 in the presence of rectal secretions collected from treated animals.
RESULTS:
Plasma drug concentrations with 50 mg/kg raltegravir or elvitegravir were within the range seen in humans receiving 400-800 mg of raltegravir or 800 mg of unboosted elvitegravir but lower than with 150 mg of elvitegravir boosted with cobicistat. AUC0-24 values for dolutegravir increased proportionally with the dose, with a calculated human-equivalent dose of 20 mg/kg. Elvitegravir showed the highest penetration in rectal and vaginal fluids despite the absence of pharmacological boosting, followed by raltegravir and dolutegravir. Rectal secretions collected at 24 h from treated macaques blocked infection of TZM-bl cells by 50% at dilutions of 1/1000 (raltegravir), 1/800 (dolutegravir) and >1/30 000 (elvitegravir).
CONCLUSIONS:
We defined macaque doses of HIV integrase inhibitors that recapitulate human clinical doses, which will facilitate efficacy and dose escalation studies in macaques. High and sustained drug concentrations and activity in mucosal secretions suggest that integrase inhibitors are promising candidates for HIV prevention.
AuthorsIvana Massud, Amy Martin, Chuong Dinh, James Mitchell, Leecresia Jenkins, Walid Heneine, Chou-Pong Pau, J Gerardo García-Lerma
JournalThe Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 70 Issue 5 Pg. 1473-81 (May 2015) ISSN: 1460-2091 [Electronic] England
PMID25630643 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)
CopyrightPublished by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Chemical References
  • Anti-HIV Agents
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Quinolones
  • Raltegravir Potassium
  • elvitegravir
  • dolutegravir
Topics
  • Administration, Oral
  • Animals
  • Anti-HIV Agents (administration & dosage, pharmacokinetics)
  • Bodily Secretions (chemistry)
  • Chromatography, High Pressure Liquid
  • Female
  • Heterocyclic Compounds, 3-Ring (administration & dosage, pharmacokinetics)
  • Macaca mulatta
  • Mucous Membrane (chemistry)
  • Oxazines
  • Piperazines
  • Plasma (chemistry)
  • Pyridones
  • Quinolones (administration & dosage, pharmacokinetics)
  • Raltegravir Potassium (administration & dosage, pharmacokinetics)
  • Rectum (chemistry)
  • Tandem Mass Spectrometry
  • Vagina (chemistry)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: